Efficacy of chondroitin sulfate for painful knee osteoarthritis

A one-year, randomized, double-blind, multicenter clinical study in Japan

Mitsuhiro Morita, Kotaro Yamada, Hideki Date, Kazue Hayakawa, Hidetomo Sakurai, Harumoto Yamada

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We explored the effects of chondroitin sulfate on knee osteoarthritis in a one-year, randomized, doubleblind, dose-comparison study. Patients with painful, Kellgren-Lawrence grade 2-3, osteoarthritis of the knee were treated with oral chondroitin sulfate at a dose of either 260 mg/d (low-dose group, control group) or 1560 mg/d (high-dose group). Symptoms were evaluated by the Lequesne's index and visual analog scale for pain. We made subgroup analyses according to background symptom severity (Lequesne's index ≥8 or <8) in 73 patients. Serum level of cartilage oligomeric matrix protein and hyaluronic acid were also determined. In the subgroup with severe symptoms (Lequesne's index ≥8), the chondroitin sulfate dose of 1560 mg/d improved pain faster after 6 and 9 months' therapy. However, no dose-related effects were found on cartilage oligomeric matrix protein or hyaluronic acid levels. Chondroitin sulfate also had good tolerability. We conclude that chondroitin sulfate is useful for pain control in knee osteoarthritis.

Original languageEnglish
Pages (from-to)163-171
Number of pages9
JournalBiological and Pharmaceutical Bulletin
Volume41
Issue number2
Publication statusPublished - 01-01-2018

Fingerprint

Chondroitin Sulfates
Knee Osteoarthritis
Multicenter Studies
Japan
Cartilage Oligomeric Matrix Protein
Hyaluronic Acid
Pain
Pain Measurement
Clinical Studies
Control Groups
Serum

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

Morita, Mitsuhiro ; Yamada, Kotaro ; Date, Hideki ; Hayakawa, Kazue ; Sakurai, Hidetomo ; Yamada, Harumoto. / Efficacy of chondroitin sulfate for painful knee osteoarthritis : A one-year, randomized, double-blind, multicenter clinical study in Japan. In: Biological and Pharmaceutical Bulletin. 2018 ; Vol. 41, No. 2. pp. 163-171.
@article{31ef6b01d11844cfb38381adf4b84a8f,
title = "Efficacy of chondroitin sulfate for painful knee osteoarthritis: A one-year, randomized, double-blind, multicenter clinical study in Japan",
abstract = "We explored the effects of chondroitin sulfate on knee osteoarthritis in a one-year, randomized, doubleblind, dose-comparison study. Patients with painful, Kellgren-Lawrence grade 2-3, osteoarthritis of the knee were treated with oral chondroitin sulfate at a dose of either 260 mg/d (low-dose group, control group) or 1560 mg/d (high-dose group). Symptoms were evaluated by the Lequesne's index and visual analog scale for pain. We made subgroup analyses according to background symptom severity (Lequesne's index ≥8 or <8) in 73 patients. Serum level of cartilage oligomeric matrix protein and hyaluronic acid were also determined. In the subgroup with severe symptoms (Lequesne's index ≥8), the chondroitin sulfate dose of 1560 mg/d improved pain faster after 6 and 9 months' therapy. However, no dose-related effects were found on cartilage oligomeric matrix protein or hyaluronic acid levels. Chondroitin sulfate also had good tolerability. We conclude that chondroitin sulfate is useful for pain control in knee osteoarthritis.",
author = "Mitsuhiro Morita and Kotaro Yamada and Hideki Date and Kazue Hayakawa and Hidetomo Sakurai and Harumoto Yamada",
year = "2018",
month = "1",
day = "1",
language = "English",
volume = "41",
pages = "163--171",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "2",

}

Efficacy of chondroitin sulfate for painful knee osteoarthritis : A one-year, randomized, double-blind, multicenter clinical study in Japan. / Morita, Mitsuhiro; Yamada, Kotaro; Date, Hideki; Hayakawa, Kazue; Sakurai, Hidetomo; Yamada, Harumoto.

In: Biological and Pharmaceutical Bulletin, Vol. 41, No. 2, 01.01.2018, p. 163-171.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of chondroitin sulfate for painful knee osteoarthritis

T2 - A one-year, randomized, double-blind, multicenter clinical study in Japan

AU - Morita, Mitsuhiro

AU - Yamada, Kotaro

AU - Date, Hideki

AU - Hayakawa, Kazue

AU - Sakurai, Hidetomo

AU - Yamada, Harumoto

PY - 2018/1/1

Y1 - 2018/1/1

N2 - We explored the effects of chondroitin sulfate on knee osteoarthritis in a one-year, randomized, doubleblind, dose-comparison study. Patients with painful, Kellgren-Lawrence grade 2-3, osteoarthritis of the knee were treated with oral chondroitin sulfate at a dose of either 260 mg/d (low-dose group, control group) or 1560 mg/d (high-dose group). Symptoms were evaluated by the Lequesne's index and visual analog scale for pain. We made subgroup analyses according to background symptom severity (Lequesne's index ≥8 or <8) in 73 patients. Serum level of cartilage oligomeric matrix protein and hyaluronic acid were also determined. In the subgroup with severe symptoms (Lequesne's index ≥8), the chondroitin sulfate dose of 1560 mg/d improved pain faster after 6 and 9 months' therapy. However, no dose-related effects were found on cartilage oligomeric matrix protein or hyaluronic acid levels. Chondroitin sulfate also had good tolerability. We conclude that chondroitin sulfate is useful for pain control in knee osteoarthritis.

AB - We explored the effects of chondroitin sulfate on knee osteoarthritis in a one-year, randomized, doubleblind, dose-comparison study. Patients with painful, Kellgren-Lawrence grade 2-3, osteoarthritis of the knee were treated with oral chondroitin sulfate at a dose of either 260 mg/d (low-dose group, control group) or 1560 mg/d (high-dose group). Symptoms were evaluated by the Lequesne's index and visual analog scale for pain. We made subgroup analyses according to background symptom severity (Lequesne's index ≥8 or <8) in 73 patients. Serum level of cartilage oligomeric matrix protein and hyaluronic acid were also determined. In the subgroup with severe symptoms (Lequesne's index ≥8), the chondroitin sulfate dose of 1560 mg/d improved pain faster after 6 and 9 months' therapy. However, no dose-related effects were found on cartilage oligomeric matrix protein or hyaluronic acid levels. Chondroitin sulfate also had good tolerability. We conclude that chondroitin sulfate is useful for pain control in knee osteoarthritis.

UR - http://www.scopus.com/inward/record.url?scp=85041488920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041488920&partnerID=8YFLogxK

M3 - Article

VL - 41

SP - 163

EP - 171

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 2

ER -